Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)
China
· Delayed Price · Currency is CNY 54.16
+2.66 (5.17%)
Mar 10, 2026, 3:00 PM CST
SHA:688091 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 317.08 | 173.03 | 359.75 | 235.7 | 4.08 | Upgrade
|
| Other Revenue | - | 0.51 | 0.51 | 0.25 | - | Upgrade
|
| Revenue | 317.08 | 173.53 | 360.25 | 235.96 | 4.08 | Upgrade
|
| Revenue Growth (YoY) | 82.72% | -51.83% | 52.68% | 5686.76% | - | Upgrade
|
| Cost of Revenue | - | 13.34 | 23.62 | 16.97 | 0.3 | Upgrade
|
| Gross Profit | 317.08 | 160.2 | 336.63 | 218.99 | 3.78 | Upgrade
|
| Selling, General & Admin | - | 143.05 | 147.57 | 98.64 | 17.29 | Upgrade
|
| Research & Development | - | 37.2 | 22.45 | 7.93 | 13.24 | Upgrade
|
| Other Operating Expenses | 255 | 1.01 | 1.61 | 0.9 | 0.03 | Upgrade
|
| Operating Expenses | 255 | 176.21 | 177.07 | 109.51 | 30.77 | Upgrade
|
| Operating Income | 62.08 | -16.01 | 159.57 | 109.48 | -26.99 | Upgrade
|
| Interest Expense | - | -0.7 | -0.27 | - | -0.59 | Upgrade
|
| Interest & Investment Income | - | 25.04 | 34.35 | 30.32 | 8.6 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.12 | -0.09 | -0.05 | -0 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | 60.96 | 8.24 | 193.59 | 139.79 | -19 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.42 | 0.9 | 3.25 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0 | - | - | - | Upgrade
|
| Other Unusual Items | - | -3.42 | -7.11 | 8.87 | 6.47 | Upgrade
|
| Pretax Income | 60.96 | 4.82 | 186.9 | 149.56 | -9.28 | Upgrade
|
| Income Tax Expense | -3.17 | -2.16 | 25.35 | 6.71 | -5.28 | Upgrade
|
| Net Income | 64.13 | 6.98 | 161.55 | 142.85 | -4 | Upgrade
|
| Net Income to Common | 64.13 | 6.98 | 161.55 | 142.85 | -4 | Upgrade
|
| Net Income Growth | 819.42% | -95.68% | 13.09% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 207 | 233 | 158 | 206 | 156 | Upgrade
|
| Shares Outstanding (Diluted) | 207 | 233 | 158 | 206 | 156 | Upgrade
|
| Shares Change (YoY) | -11.02% | 46.80% | -23.24% | 32.68% | 2.51% | Upgrade
|
| EPS (Basic) | 0.31 | 0.03 | 1.02 | 0.69 | -0.03 | Upgrade
|
| EPS (Diluted) | 0.31 | 0.03 | 1.02 | 0.69 | -0.03 | Upgrade
|
| EPS Growth | 933.33% | -97.06% | 47.34% | - | - | Upgrade
|
| Free Cash Flow | - | -40.6 | 77.77 | 74.9 | -51.93 | Upgrade
|
| Free Cash Flow Per Share | - | -0.17 | 0.49 | 0.36 | -0.33 | Upgrade
|
| Dividend Per Share | - | - | 0.031 | 0.210 | - | Upgrade
|
| Dividend Growth | - | - | -85.22% | - | - | Upgrade
|
| Gross Margin | 100.00% | 92.31% | 93.44% | 92.81% | 92.75% | Upgrade
|
| Operating Margin | 19.58% | -9.23% | 44.29% | 46.40% | -661.96% | Upgrade
|
| Profit Margin | 20.23% | 4.02% | 44.84% | 60.54% | -98.03% | Upgrade
|
| Free Cash Flow Margin | - | -23.40% | 21.59% | 31.74% | -1273.49% | Upgrade
|
| EBITDA | 73.24 | -4.85 | 167.45 | 115.91 | -20.4 | Upgrade
|
| EBITDA Margin | 23.10% | -2.79% | 46.48% | 49.12% | - | Upgrade
|
| D&A For EBITDA | 11.16 | 11.16 | 7.88 | 6.43 | 6.59 | Upgrade
|
| EBIT | 62.08 | -16.01 | 159.57 | 109.48 | -26.99 | Upgrade
|
| EBIT Margin | 19.58% | -9.23% | 44.29% | 46.40% | - | Upgrade
|
| Effective Tax Rate | - | - | 13.56% | 4.48% | - | Upgrade
|
| Revenue as Reported | - | 173.53 | 360.25 | 235.96 | 4.08 | Upgrade
|
| Advertising Expenses | - | - | - | - | 0.33 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.